Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Enfoque inmunoterapéutico altamente selectivo para el tratamiento de la leucemia linfática crónica

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20151125002
Publicado:
27/11/2015
Caducidad:
27/11/2016
Resumen:
Una universidad alemana ofrece un nuevo tratamiento para la leucemia linfática crónica basada en células con una selectividad considerablemente mejorada de eliminación de células blanco. Al mismo tiempo se reducen los efectos adversos en células normales. El receptor de antígeno quimérico consiste en un fragmento de anticuerpo de cadena sencilla derivado de células B (scFv) dirigido contra TOSO. Este ectodominio se fusiona con un dominio de activación de célula T CD28 coestimulatorio, finalmente seguido por un dominio CD3¿. El receptor se introduce en células T de sangre periférica alogénica o autóloga mediante transferencia del gen retroviral. Se buscan socios industriales con el fin de establecer acuerdos de licencia y continuar con la investigación.

Details

Tittle:
Highly selective immunotherapeutic approach to chronic lymphatic leukemia treatment
Summary:
A German university offers a new treatment approach for chronic lymphatic leukemia. It is based on cells with strongly improved selectivity of target cell killing. Adverse effects on normal cells are at the same time reduced. Industrial partners are sought for licensing and further research.
Description:
Cancer-immunotherapy is currently attracting more attention thanks to novel genetic engineering technologies. The most promising approach is the chimeric antigen receptor (CAR) technique for redirecting hereby modified T cells against cancer-associated antigens.

TOSO (also known as Faim 3) is a type I transmembrane protein that is involved in Fas-induced apoptosis. It is overexpressed on chronic lymphatic leukemia (CLL) cells, whereas the level of expression is correlated with the aggressiveness of the disease. In contrast, TOSO is only weakly expressed on normal lymphocytes. This expression profile qualifies TOSO as target antigen for immunotherapeutic anti-leukemia approaches by means of CAR T cells.

A German university now presents a CAR that consists of a B cell-derived single chain antibody fragment (scFv) directed against TOSO. This ectodomain is fused with a co-stimulatory CD28 T cell activation domain, finally followed by a CD3¿ domain. The receptor is introduced into allogenic or autologous peripheral blood T cells by retroviral gene transfer.

Cell-based assays show high killing specificity of the anti-TOSO CAR T cells against CLL cells, whereas normal B cells remain intact. The discrimination is strongly improved in comparison to previously engineered anti-CD19 CAR T cells that are currently used in clinical studies.

The described anti-TOSO CAR T cells thus have a strongly improved selectivity of target cell killing. The reduction of adverse effects on normal cells provides a competitive advantage against all other CAR T cell approaches that are currently on the market.

Partners from pharmaceutical industry are sought for licensing and further research.
Advantages and Innovations:
· Novel immunotherapeutic approach of the CAR T cell technology
· High selectivity for CLL cells with lower adverse effects on normal cells than approaches currently on the market
· Improved alternative approach for B-CLL treatment in comparison to anti-CD19 CAR T cells
Stage of Development:
Prototype available for demonstration
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
A European patent application is pending.

Partner sought

Type and Role of Partner Sought:
The university offers a patent license as well as a research collaboration with licensing option to partners from pharmaceutical industry with activities in oncology.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06001012 Investigaciones médicas
03004007 Pharmaceutics
06001015 Productos farmacéuticos / medicamentos